AMO Pharma reveals data from myotonic dystrophy study
Clinically significant results have emerged from trial evaluating the company’s AMO-02 candidate
Read Moreby John Pinching | Sep 8, 2023 | News | 0
Clinically significant results have emerged from trial evaluating the company’s AMO-02 candidate
Read Moreby John Pinching | Aug 30, 2023 | News | 0
The therapy involves treating individuals with atherosclerotic cardiovascular disease
Read Moreby John Pinching | Jul 14, 2023 | News | 0
CAR-T cell therapy being researched among patients with relapsed or refractory B cell non-Hodgkin lymphoma
Read Moreby John Pinching | Jul 13, 2023 | News | 0
Results are from company’s phase 2 head and neck cancer trial with lead NOX inhibitor candidate
Read Moreby John Pinching | Jul 10, 2023 | News | 0
Period to remission was shortened with esketamine nasal spray in both sub-groups within study
Read Moreby John Pinching | Jul 6, 2023 | News | 0
Patients treated with Kesimpta experienced considerable decreases in relapse rates
Read Moreby John Pinching | Jul 5, 2023 | News | 0
SENS-401 has been developed for hearing preservation among adult patients following cochlear implantation
Read Moreby John Pinching | Jul 4, 2023 | News | 0
Therapy has been developed to reduce the frequency, duration and severity of migraine attacks
Read Moreby John Pinching | Jun 29, 2023 | News | 0
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis
Read Moreby John Pinching | Jun 28, 2023 | News | 0
GLORIA trial shows increased survival levels among newly diagnosed brain cancer patients
Read Moreby John Pinching | Jun 28, 2023 | News | 0
Trial involved over 450 women across Europe, Turkey and Canada who were unsuitable for hormone therapy
Read Moreby John Pinching | Jun 20, 2023 | News | 0
Immunological disorder therapy data to be shared at International Conference on Redox Medicine
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479